Puma Biotechnology Inc
NASDAQ:PBYI

Watchlist Manager
Puma Biotechnology Inc Logo
Puma Biotechnology Inc
NASDAQ:PBYI
Watchlist
Price: 2.79 USD 1.45%
Market Cap: 137m USD
Have any thoughts about
Puma Biotechnology Inc?
Write Note

Gross Margin
Puma Biotechnology Inc

69.3%
Current
75%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
69.3%
=
Gross Profit
168.8m
/
Revenue
243.6m

Gross Margin Across Competitors

Country US
Market Cap 136.9m USD
Gross Margin
69%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 311.8B USD
Gross Margin
67%
Country US
Market Cap 140.7B USD
Gross Margin
60%
Country US
Market Cap 115.7B USD
Gross Margin
78%
Country US
Market Cap 102.7B USD
Gross Margin
86%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 134.4B AUD
Gross Margin
52%
Country US
Market Cap 78B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 36B EUR
Gross Margin
89%
No Stocks Found

Puma Biotechnology Inc
Glance View

Market Cap
136.9m USD
Industry
Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company. The company is headquartered in Los Angeles, California and currently employs 196 full-time employees. The company went IPO on 2012-03-21. The firm is focused on the development and commercialization of products to enhance cancer care. The firm's lead product is NERLYNX, an oral version of neratinib, which is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the human epidermal growth factor receptors, HER1, HER2 and HER4. The company is primarily focused on the development and commercialization of the oral version of neratinib, and its advanced drug candidates are directed at the treatment of HER2-positive breast cancer and HER2 mutated cancers. Its other products include PB272 (neratinib, intravenous), PB357, and certain related compounds. Its neratinib has clinical application in the treatment of several other cancers as well, including other tumor types that over-express or have a mutation in HER2 or epidermal growth factor receptor (EGFR), such as breast cancer, cervical cancer, lung cancer, or other solid tumors.

PBYI Intrinsic Value
4.48 USD
Undervaluation 38%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
69.3%
=
Gross Profit
168.8m
/
Revenue
243.6m
What is the Gross Margin of Puma Biotechnology Inc?

Based on Puma Biotechnology Inc's most recent financial statements, the company has Gross Margin of 69.3%.